Abstract
Selective GluN2B/N-methyl-D-aspartate receptor (NMDAR) antagonists have exposed their clinical effectiveness in a cluster of neurodegenerative diseases, such as epilepsy, Alzheimer’s disease, Parkinson’s disease, pain, and depression. Hence, GluN2B/NMDARs are considered to be a prospective target for the management of neurodegenerative diseases. Here, we have discussed the current results and significance of subunit selective GluN2B/NMDAR antagonists to pave the way for the establishment of new, safe, and economical drug candidates in the near future. By using summarized data of selective GluN2B/NMDAR antagonists, medicinal chemists are certainly a step closer to the goal of improving the therapeutic and side effect profile of selective antagonists. Outlined summary of designing strategies, synthetic schemes, and pharmacological evaluation studies reinvigorate efforts to identify, modify, and synthesize novel GluN2B/NMDAR antagonists for treating neurodegenerative diseases.
Keywords: GluN2B/NMDAR, design, synthesis, pharmacological studies, antagonists, diseases.
Graphical Abstract
CNS & Neurological Disorders - Drug Targets
Title:GluN2B/N-methyl-D-aspartate Receptor Antagonists: Advances in Design, Synthesis, and Pharmacological Evaluation Studies
Volume: 20 Issue: 9
Author(s): Vinod Ugale*, Ashish Dhote, Rushikesh Narwade, Saurabh Khadse, P. Narayana Reddy and Atul Shirkhedkar
Affiliation:
- Department of Pharmaceutical Chemistry, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Dist: Dhule (MS) 425405,India
Keywords: GluN2B/NMDAR, design, synthesis, pharmacological studies, antagonists, diseases.
Abstract: Selective GluN2B/N-methyl-D-aspartate receptor (NMDAR) antagonists have exposed their clinical effectiveness in a cluster of neurodegenerative diseases, such as epilepsy, Alzheimer’s disease, Parkinson’s disease, pain, and depression. Hence, GluN2B/NMDARs are considered to be a prospective target for the management of neurodegenerative diseases. Here, we have discussed the current results and significance of subunit selective GluN2B/NMDAR antagonists to pave the way for the establishment of new, safe, and economical drug candidates in the near future. By using summarized data of selective GluN2B/NMDAR antagonists, medicinal chemists are certainly a step closer to the goal of improving the therapeutic and side effect profile of selective antagonists. Outlined summary of designing strategies, synthetic schemes, and pharmacological evaluation studies reinvigorate efforts to identify, modify, and synthesize novel GluN2B/NMDAR antagonists for treating neurodegenerative diseases.
Export Options
About this article
Cite this article as:
Ugale Vinod*, Dhote Ashish , Narwade Rushikesh , Khadse Saurabh , Reddy Narayana P. and Shirkhedkar Atul , GluN2B/N-methyl-D-aspartate Receptor Antagonists: Advances in Design, Synthesis, and Pharmacological Evaluation Studies, CNS & Neurological Disorders - Drug Targets 2021; 20 (9) . https://dx.doi.org/10.2174/1871527320666210309141627
DOI https://dx.doi.org/10.2174/1871527320666210309141627 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Oxido-reductase Activity of the Apoptosis Inducing Factor: A Promising Pharmacological Tool?
Current Pharmaceutical Design Mitochondrial-Targeted Plastoquinone Derivatives. Effect on Senescence and Acute Age-Related Pathologies
Current Drug Targets Nanoplatforms for Delivery of siRNA to the Eye
Current Pharmaceutical Design Rational Basis for Nutraceuticals in the Treatment of Glaucoma
Current Neuropharmacology Ocular Toxicities in Cancer Therapy: Still Overlooked
Current Cancer Therapy Reviews Proliferative Retinopathies: Animal Models and Therapeutic Opportunities
Current Neurovascular Research Drug Therapy of Neuropathic Pain: Current Developments and Future Perspectives
Current Drug Targets Genetic Basis of Mitochondrial Optic Neuropathies
Current Molecular Medicine Ryanodine Receptor Patents
Recent Patents on Biotechnology Metal Complexes, their Cellular Targets and Potential for Cancer Therapy
Current Pharmaceutical Design Neuroinflammation and Neuroprotection: An Update on (Future) Neurotrophin-Related Strategies in Multiple Sclerosis Treatment
Current Medicinal Chemistry Melatonin As a Modulator of Degenerative and Regenerative Signaling Pathways in Injured Retinal Ganglion Cells
Current Pharmaceutical Design Double-Edged Sword of Novel Anti-Cancer Treatment: Proteasome Inhibition in the Growth Plate Causes Impairment of Longitudinal Bone Growth
Current Pediatric Reviews Physiopathological Roles of P2X Receptors in the Central Nervous System
Current Medicinal Chemistry Virus-Associated Vasculitides
Current Immunology Reviews (Discontinued) Calcium-engaged Mechanisms of Nongenomic Action of Neurosteroids
Current Neuropharmacology Neurological Disorders of Purine and Pyrimidine Metabolism
Current Topics in Medicinal Chemistry Competitive Gly/NMDA Receptor Antagonists
Current Topics in Medicinal Chemistry The Role of Melatonin in Multiple Sclerosis, Huntington's Disease and Cerebral Ischemia
CNS & Neurological Disorders - Drug Targets Withdrawn: Mesenchymal Stem Cell-derived Exosomes for Treatment of Ischemic Stroke
Current Stem Cell Research & Therapy